These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 22362907)

  • 1. Effects of frequent hemodialysis on measures of CKD mineral and bone disorder.
    Daugirdas JT; Chertow GM; Larive B; Pierratos A; Greene T; Ayus JC; Kendrick CA; James SH; Miller BW; Schulman G; Salusky IB; Kliger AS;
    J Am Soc Nephrol; 2012 Apr; 23(4):727-38. PubMed ID: 22362907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
    Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
    Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nocturnal but not short hours quotidian hemodialysis requires an elevated dialysate calcium concentration.
    Al-Hejaili F; Kortas C; Leitch R; Heidenheim AP; Clement L; Nesrallah G; Lindsay RM
    J Am Soc Nephrol; 2003 Sep; 14(9):2322-8. PubMed ID: 12937309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphorus Counting Table for the control of serum phosphorus levels without phosphate binders in hemodialysis patients.
    Bertonsello-Catto VR; Lucca LJ; da Costa JAC
    Clin Nutr ESPEN; 2019 Aug; 32():153-157. PubMed ID: 31221281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients receiving frequent hemodialysis have better health-related quality of life compared to patients receiving conventional hemodialysis.
    Garg AX; Suri RS; Eggers P; Finkelstein FO; Greene T; Kimmel PL; Kliger AS; Larive B; Lindsay RM; Pierratos A; Unruh M; Chertow GM;
    Kidney Int; 2017 Mar; 91(3):746-754. PubMed ID: 28094031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of phosphate binders in adult patients with end stage renal disease receiving hemodialysis: a systematic review.
    Gasu V; Ashong M; Seferi A; Fitzpatrick A
    JBI Database System Rev Implement Rep; 2019 Jan; 17(1):49-73. PubMed ID: 30204711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial.
    Dwyer JP; Sika M; Schulman G; Chang IJ; Anger M; Smith M; Kaplan M; Zeig S; Koury MJ; Blumenthal SS; Lewis JB;
    Am J Kidney Dis; 2013 May; 61(5):759-66. PubMed ID: 23369827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis.
    Chen L; He JX; Chen YY; Ling YS; Lin CH; Guan TJ
    Ren Fail; 2018 Nov; 40(1):15-21. PubMed ID: 29295646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients.
    Takahashi Y; Tanaka A; Nakamura T; Fukuwatari T; Shibata K; Shimada N; Ebihara I; Koide H
    Kidney Int; 2004 Mar; 65(3):1099-104. PubMed ID: 14871431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-center hemodialysis six times per week versus three times per week.
    ; Chertow GM; Levin NW; Beck GJ; Depner TA; Eggers PW; Gassman JJ; Gorodetskaya I; Greene T; James S; Larive B; Lindsay RM; Mehta RL; Miller B; Ornt DB; Rajagopalan S; Rastogi A; Rocco MV; Schiller B; Sergeyeva O; Schulman G; Ting GO; Unruh ML; Star RA; Kliger AS
    N Engl J Med; 2010 Dec; 363(24):2287-300. PubMed ID: 21091062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorus balance calculator: an individualized tool for treatment of hyperphosphatemia in hemodialysis patients.
    Wang M; Xiao J; Du Q; Zhang W; Zhang J; Yan Z; Luo J; Yu C; Ye Z; Chen J
    Nephrol Dial Transplant; 2024 Jun; 39(7):1159-1170. PubMed ID: 38037501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group.
    Slatopolsky EA; Burke SK; Dillon MA
    Kidney Int; 1999 Jan; 55(1):299-307. PubMed ID: 9893140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control of parathyroid function in patients with a short history of hemodialysis.
    Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
    Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The economic impact of improving phosphate binder therapy adherence and attainment of guideline phosphorus goals in hemodialysis patients: a Medicare cost-offset model.
    Ramakrishnan K; Braunhofer P; Newsome B; Lubeck D; Wang S; Deuson J; Claxton AJ
    Adv Ther; 2014 Dec; 31(12):1272-86. PubMed ID: 25479935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeled Daily Ingested, Absorbed and Bound Phosphorus: New Measures of Mineral Balance in Hemodialysis Patients.
    Kapoian T; Khalil S; O'Mara NB; Brink DM; Daugirdas JT
    Am J Nephrol; 2019; 49(5):368-376. PubMed ID: 30939469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding.
    Fukagawa M; Kido R; Komaba H; Onishi Y; Yamaguchi T; Hasegawa T; Kurita N; Fukuma S; Akizawa T; Fukuhara S
    Am J Kidney Dis; 2014 Jun; 63(6):979-87. PubMed ID: 24119541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
    Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in 3-month mineral and bone disorder patterns were associated with all-cause mortality in prevalent hemodialysis patients with secondary hyperparathyroidism.
    Kato C; Fujii N; Miyakoshi C; Asada S; Onishi Y; Fukuma S; Nomura T; Wada M; Fukagawa M; Fukuhara S; Akizawa T
    BMC Nephrol; 2020 Oct; 21(1):432. PubMed ID: 33045994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intradialytic changes of serum magnesium and their relation to hypotensive episodes in hemodialysis patients on different dialysates.
    Elsharkawy MM; Youssef AM; Zayoon MY
    Hemodial Int; 2006 Oct; 10 Suppl 2():S16-23. PubMed ID: 17022745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.